Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
345
resultados
Última actualización
16/10/2026 [07:35:00]
Resultados 75 a 100 de 345
Resumen de: CN122814900A
本发明公开了一种可以分辨APOE4基因杂合子和纯合子的指尖血试纸条。不仅可以用于快速检测受试人是否APOE ε4基因的携带者，而且还能进一步区分APOE ε4基因的携带者是杂合子还是纯合子。所述试纸条包括PVC底板，所述PVC底板上铺设有依次搭接的样本垫、滤血垫、结合垫、硝酸纤维层析垫和吸水垫；所述结合垫上涂有与抗人ApoE单克隆抗体结合的胶体金颗粒、彩色乳胶颗粒或荧光颗粒；所述硝酸纤维层析垫上靠近结合垫的一侧设有检测线T1和T2线、靠近吸水垫的一侧设有对照控制线C线，所述检测线T1线上涂有抗人ApoE4单克隆抗体，所述检测线T2线上涂有抗人ApoE多克隆抗体，所述对照控制线C线上涂有相应的抗IgG多克隆抗体。
Resumen de: WO2025182761A1
Provided is a method for detecting GFAP in a sample by immunoassay, the method including a first step for forming a complex of a first antibody and GFAP, and a second step for forming a complex of a second antibody and GFAP, the first antibody binding to a region consisting of amino acids at positions 111 to 115 in the amino acid sequence of GFAP.
Resumen de: WO2025037271A1
Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from subjects, involving the use of a capture antibody that binds to a tau epitope, and a detection antibody that binds to an epitope comprising amino acids residues that span the junction of Exon 4 and Exon 5 of CNS-derived tau.
Resumen de: JP2026531970A
0001 本開示は、ウイルスベクターを含有する試料中の少なくとも１つの宿主細胞タンパク質（ＨＣＰ）不純物を濃縮する、同定する、および／または特性評価するための方法を提供する。ＨＣＰ不純物は、ビーズベースのペプチドリガンドのライブラリーの利用を介して濃縮することができる。濃縮したＨＣＰは、続いて、酵素消化に供されてペプチドを生成し、このペプチドを液体クロマトグラフィー－質量分析（ＬＣ－ＭＳ）によって同定して、当該少なくとも１つのＨＣＰ不純物を特異的に同定するおよび／または特性評価することができる。 【選択図】図１Ａ
Resumen de: JP2026149362A
0001 【課題】被験者の糞便中の細菌の情報に基づき、低骨量又は低骨量リスクを検査する方法を提供する。 【解決手段】被験者の糞便中細菌におけるセガテラ・コプリの存在比率を取得する工程を含む、低骨量又は将来の低骨量リスクの検査方法。 【選択図】なし
Resumen de: CN122814921A
本发明涉及生物医学检测技术领域，提供一种光激化学发光检测尿液样本中磷酸化tau蛋白的试剂盒，包括：供体微球，标记有抗人tau蛋白抗体；受体微球，标记有抗磷酸化tau蛋白抗体；供体微球和所述受体微球用于光激化学发光免疫分析。本发明的试剂盒采用双抗体夹心光激化学发光免疫分析法，通过供体微球与受体微球的协同作用产生化学发光信号，实现尿液样本中磷酸化tau蛋白的定量检测，具有均相检测、操作简便的特点。
Resumen de: US20260287576A1
0000 The invention provides, in some embodiments, a potency assay matrix for assessing potency of dopaminergic neuronal progenitor cells (DANPCs) that are intended for use in treating a neurodegenerative disease such as Parkinson's Disease. The potency assay matrix can include a bioassay for L-DOPA decarboxylase (DDC) activity. In addition to the DDC activity assay matrix, the potency assay matrix may also include one or more additional mechanism of action-based assays such as bioinformatics-based assays for determining whether the DANPCs are dopaminergic neuronal progenitor cells, for determining whether the DANPCs are likely to engraft when implanted into a subject brain, and for determining whether neuronal cells that are derived from the DANPCs are likely to produce dopamine after implantation.
Resumen de: US20260289785A1
0000 The present disclosure describes a method of quantifying analyte levels using gold nanoparticles. The present disclosure also describes a device to quantify analyte levels using gold nanoparticles and image processing of pixels isolated from a single vector. The methods, devices, and systems of the disclosure can be used to quantify analytes such as luteinizing hormone, progesterone, estradiol, or testosterone.
Resumen de: US20260287580A1
0000 The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from disease such as a neurological condition or disease. In general, detection or measurement of one or more biomarkers, such as neurofilament light chain (NfL), and combinations thereof with assays of the present disclosure, assists in the identification of disease such as neurological disease. The present disclosure also provides methods for selecting patients for treatment of neurological disease.
Resumen de: US20260287596A1
Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the invention relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, receiving a dataset comprising biomarker concentrations, wherein the dataset is from a sample obtained from a pediatric patient having at least one indication of septic shock, then determining whether the biomarker concentrations of each of the at least one biomarkers are greater than one or more pre-determined cut-off biomarker concentration, wherein the level of said biomarker correlates with a predicted outcome.
Resumen de: US20260285898A1
The present application relates to compounds based on a triterpene glycoside saponin scaffold, which bear an acyl chain comprising a photoreactive moiety and a terminal biotin, of general formula (I)The present application also relates to the use of said compounds and compositions thereof in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers as well as its use as chemical probe in photoaffinity labeling (PAL) (for photocrosslinking with interacting partners) followed by affinity purification of the covalent complex and MS-based proteomics for target identification and elucidation of the protein receptor.
Resumen de: AU2025226208A1
The present invention relates to an antigen combination comprising Treponema pallidum (Tp) antigens. The present invention also relates to vectors, polynucleotides, host cells and methods for producing such antigen combinations. The present invention also relates to method and uses of such antigen combinations. The present invention also relates to compositions, assays and kits and the methods and uses thereof.
Resumen de: US20260287581A1
0000 The present disclosure relates to a method for estimating the amount of a tau protein accumulated in the brain. One of a capture antibody and a detection antibody which are used in the method is an antibody which recognizes an amino acid sequence in a middle part of a phosphorylated tau protein, and the other is an antibody which recognizes a phosphorylated epitope including a phosphorylated amino acid residue of the phosphorylated tau protein.
Resumen de: US20260287585A1
Detecting a binding event of specific binding pair-forming substances, comprising includes: providing a layer of a first specific binding pair-forming substance (SBPS) on a substrate, providing an enclosure of the layer with a first dielectric medium (DM) rinsing the enclosure for a first time period with a second DM, restoring the first DM in the enclosure following the rinsing, feeding a solution of a second SBPS to the enclosure to cause an interaction between the first second SBPS following the restoring, incubating the enclosure for a second time period, the interaction including a binding event when the first and second SBPS provide a specific binding pair, detecting a shift in a parameter representative of a layer dielectric function following the incubating, comparing the shift with a threshold, whereby when the shift exceeds the threshold the binding event has occurred.
Resumen de: US20260287598A1
0000 A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.
Resumen de: US20260287599A1
Embodiments of the present disclosure pertain to methods of assessing pain in a subject by receiving one or more measured levels of glycine receptors of the subject; and correlating differentially expressed levels of the glycine receptors to pain. The methods of the present disclosure may also include a step of implementing a treatment decision based on the assessment. In some embodiments, the methods of the present disclosure may be repeated after implementing the treatment decision. Additional embodiments of the present disclosure pertain to systems for assessing pain in a subject. In some embodiments, the systems include computer-readable storage mediums with program codes that implement the methods of the present disclosure.
Resumen de: US20260287600A1
0000 Methods, reagents, kits and systems for analyzing different proteoforms of proteins of interest are provided. The provided methods, systems, etc. provide detection, characterization and quantitation of proteoforms for different biologically relevant proteins for monitoring and characterizing biological processes.
Resumen de: US20260287601A1
A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the temporal biomarkers of traumatic brain injury and their methods of use. In some embodiments, the temporal biomarkers are synthetic peptides comprising the HCDR3 sequences identified using the disclosed pipeline. In some aspects, the synthetic peptides have less than 30 amino acid residues and comprise a biotin scaffold that is linked to the HCDR3 sequences.
Resumen de: WO2026196014A1
The invention relates to a method for refined stage classification of a hereditary, preferably monogenic, neurodegenerative diseases mediated by an impairment of a disease-mediating gene, in disease-affected subjects. The invention also relates to diagnosis of a patient with the neurodegenerative diseases comprising classifying said patient in a stage of said disease. The subgroups react differently to treatment. In summary, the present inventors used a preclinical induced neuronal model to predict drug effectiveness in clinical trials, and have found a new dimension on prescreening patients before entering in clinical trials, thereby reducing the trial's failure.
Resumen de: US20260287593A1
The present invention provides methods and systems for antibody-independent spatial proteomics analysis using wavelength-specific click chemistry. Photoactivatable click chemistry reagents responsive to distinct wavelengths (UV, blue, green, red) are introduced into biological samples and selectively activated using laser matrix systems with submicron spatial control. Wavelength-specific activation enables simultaneous labeling of proteins at multiple subcellular locations or tissue regions, followed by mass spectrometry analysis to determine spatial protein distributions with subcellular resolution. The technology eliminates antibody dependencies while providing comprehensive proteome coverage (1000+ proteins per spatial region) at significantly reduced cost and time compared to conventional methods. Applications include clinical cancer diagnostics, drug discovery screening, and research applications across diverse biological systems including cell cultures, tissue sections, and FFPE clinical specimens.
Resumen de: US20260285900A1
Disclosed herein are methods of oxidizing a guanidine group comprising contacting a compound or peptide having a guanidine group with a 9,10-phenanthrenequinone or derivative providing compound with an aldehyde group in place of the guanidine group. In certain embodiments, the guanidine group is an arginine amino acid within a protein. In certain embodiments, this disclosure relates to compositions comprising 9,10-phenanthrenequinone derivatives as provided herein.
Resumen de: US20260285956A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: WO2026198565A1
A method and related system for immunodiagnostic assessment of an antigen in a sample. A sample is mixed in a sample tube (i.e., cartridge) with magnetic beads and first visualization reagent which are both conjugated with antibodies for the antigen and, if the sample includes the antigen, forms magnetic immunocomplexes. The sample tube is attached to a base having a visualization chamber, the sample is flowed into the base from the sample tube, and the magnetic beads and, if formed, the magnetic immunocomplexes are advanced into the visualization window. A second visualization reagent adapted to react with the first visualization reagent to produce a visible change is introduced. An image is acquired of the visualization window with a smartphone to assess whether the visible change has occurred. The image of the visualization window acquired using the smartphone is evaluated to assess whether the antigen is present in the sample.
Resumen de: WO2026193586A1
Disclosed herein are methods of detecting at least two biomarkers in a DNA sample from a subject, the method comprising simultaneously, in a single test, amplifying the regions of DNA containing each of the at least two types of biomarkers in the DNA sample to produce amplified DNA; sequencing, by a sequencer, the amplified DNA to produce a sequencing read; and wherein the sequencing read identifies a presence and/or an absence of the at least two types of biomarkers, optionally, outputting a report indicating the presence or absence of the at least two types biomarkers in the DNA sample wherein the at least two types of biomarkers are selected from: (i) single nucleotide variations (SNVs), and/or insertion or deletion (indel) mutations; (ii) chromosomal copy number variations (CNVs), and (iii) gene CNVs.
Nº publicación: WO2026198475A1 24/09/2026
Solicitante:
CYMBA X LLC [US]
CYMBA X, LLC
Resumen de: WO2026198475A1
The present invention relates to an antigen-binding molecule specifically binding to methylpseudouridine or 1-methyluracil, a polynucleotide encoding it, a conjugate comprising it, and a method for producing such an antigen-binding molecule. The invention further relates to a method for detecting methylpseudouridine or 1-methyluracil, a method for detecting and/or quantifying a level of methylpseudouridine and/or 1-methyluracil, a kit for detecting presence and/or for quantifying a level of methylpseudouridine and/or 1-methyluracil, and a kit for enriching or purifying methylpseudouridine or polynucleotides containing methylpseudouridine.
BOPI
Sede Electrónica
